DDInter909 DDInter596
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) upregulates {v} (Gene) SPAG4
SPAG4 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) binds {v} (Gene) ABL1
ABL1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) downregulates {v} (Gene) SCAND1
SCAND1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Imatinib {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Doxorubicin (Compound)
Imatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Imatinib (Compound) upregulates SPAG4 (Gene) and SPAG4 (Gene) is upregulated by Doxorubicin (Compound)
Imatinib (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is upregulated by Doxorubicin (Compound)
Imatinib (Compound) binds KIT (Gene) and KIT (Gene) is upregulated by Doxorubicin (Compound)
Imatinib (Compound) binds ABL1 (Gene) and ABL1 (Gene) is downregulated by Doxorubicin (Compound)
Imatinib (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is downregulated by Doxorubicin (Compound)
Imatinib (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Doxorubicin (Compound)